We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Source: Pharmacy Times articles Data from a phase 1b study showed significantly reduced toxicity compared with conventional oral dosing. Read More

Pharmacists Reimagine Myeloma Care With Insights from ASCO

Source: Pharmacy Times articles Gabe Hinojosa, PharmD, BCOP, shares key data for pharmacists from the 2025 American Society of Clinical Oncology Annual Meeting. Read More

High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma

Source: Pharmacy Times articles Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial. Read More
Latest Data

Latest Publications

Hepatitis B and C virus infection and risk of multiple myeloma: a systematic review and meta-analysis

BMC Cancer. 2025 Jun 4;25(1):998. doi: 10.1186/s12885-025-14420-5. ABSTRACT BACKGROUND: Multiple...

Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies

Blood Cancer J. 2025 May 26;15(1):104. doi: 10.1038/s41408-025-01312-x. ABSTRACT While observation...

Email

info@myeloma360.com